Takeda to sell TachoSil surgical patch to Corza Health for 350m euros
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[TOKYO] Takeda Pharmaceutical said on Wednesday it would sell its TachoSil surgical patch product to Corza Health for 350 million euros (S$563.7 million) as the Japanese company continues to divest non-core businesses.
TachoSil, a surgical patch used for bleeding control, delivered US$160 million in sales for Takeda in the fiscal year ended March 31, 2020, the company said in a release.
To reduce debt, Takeda has pledged to dispose of US$10 billion worth of non-core assets.
Takeda is focusing on five key business areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
